Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT06333652
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Preeclampsia

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Ravulizumab — DRUG
    Intravenous infusion 100 mg/ml

Study Details

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Key Dates

Start date
Sep 1, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
14 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Revulizumab Treatment
    Subjects will receive an single-dose infusion of Ravulizumab.

Primary Outcome Measure

Alternative Complement Pathway Biomarkers at time of delivery [ Time Frame: Baseline ]

Central Contacts

  • Gonzalez Suarez
    507-284-2511

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic MinnesotaRochesterMinnesota55905
Maria L. Gonzalez Suarez, MD,PhD
[email protected]
5072844083

Find similar trials in Rochester, MN

By research site
Mayo Clinic Minnesota· Rochester, MN

Related Studies